Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dilanubicel with Cord Blood Transplant in HIV+ Cancer Patients
NCT04083170Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of dilanubicel in human immunodeficiency virus infection (HIV), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Oct 2022; status: terminated.
02
Drugs
dilanubicel
03
Conditions
human immunodeficiency virus infection (HIV)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04083170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083170.